Research Progress of Prostate Stem Cell Antigen in Bladder Cancer Treatment

In order to study the application effect of prostate stem cell antigen in the treatment of bladder cancer,several literatures have been reviewed in this paper,including the predisposition factors of bladder cancer,clinical treatment methods,progress of prostate stem cell antigen,and nanomaterial probe.This paper presents a feasible method of using luminescent nanomaterials(anti-UCNPs)as biological probes.

Fu-Zheng-Yi-Liu Formula inhibits the stem cells and metastasis of prostate cancer via tumor-associated macrophages/C-C motif chemokine ligand 5 pathway in tumor microenvironment

Prostate cancer(PCa)is the second most common malignancy among men globally.The Fu-Zheng-Yi-Liu(FZYL)Formula has been widely utilized in the treatment of PCa.This study investigates whether the FZYL Formula can inhibit PCa by tar-geting the TAMs/CCL5 pathway.We conducted in vitro co-cultures and in vivo co-injections of PCa cells and TAMs to mimic their in-teraction.Results showed that the FZYL Formula significantly reduced the proliferation,colony formation,subpopulations of PCSCs,and sphere-formation efficacy of PCa cells,even in the presence of TAM co-culture.Additionally,the Formula markedly decreased the migration,invasion,and epithelial-mesenchymal transition(EMT)of PCa cells induced by TAMs.The FZYL Formula also reversed M2 phenotype polarization in TAMs and dose-dependently reduced their CCL5 expression and secretion,with minimal cytotoxicity observed.Mechanistic studies confirmed that the TAMs/CCL5 axis is a critical target of the FZYL Formula,as the addition of exogen-ous CCL5 partially reversed the formula’s inhibitory effects on PCSCs self-renewal in the co-culture system.Importantly,the Formula also significantly inhibited the growth of PCa xenografts,bone metastasis,and PCSCs activity in vivo by targeting the TAMs/CCL5 pathway.Overall,this study not only elucidates the immunomodulatory mechanism of the FZYL Formula in PCa therapy but also highlights the TAMs/CCL5 axis as a promising therapeutic target.

Recent advances in tissue stem cells

Stem cells are undifferentiated cells capable of self-renewal and differentiation,giving rise to specialized functional cells.Stem cells are of pivotal importance for organ and tissue development,homeostasis,and injury and disease repair.Tissue-specific stem cells are a rare population residing in specific tissues and present powerful potential for regeneration when required.They are usually named based on the resident tissue,such as hematopoietic stem cells and germline stem cells.This review discusses the recent advances in stem cells of various tissues,including neural stem cells,muscle stem cells,liver progenitors,pancreatic islet stem/progenitor cells,intestinal stem cells,and prostate stem cells,and the future perspectives for tissue stem cell research.

Genetic Polymorphism of PSCA and Risk of Advanced Precancerous Gastric Lesions in a Chinese Population

Objective： To evaluate the relationship between the genetic polymorphism of prostate stem cell antigen （PSCA） and the risk of advanced precancerous gastric lesions including intestinal metaplasia（IM） and dysplasia（Dys）, a population-based study was conducted in Linqu County, a high-risk area of gastric cancer （GC） in China. Methods： The prevalence of gastric lesions including superficial gastritis（SG）, chronic atrophic gastritis（CAG）, IM and Dys was determined by histopathologic examination. The genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism （PCR-RFLP） technique. The effects of PSCA genetic variant on the risks of IM and Dys were calculated by unconditional logistic regression. Results： Multivariate analysis revealed subjects carrying PSCA rs2294008 CT/TT genotype were associated with an increased risk of IM （OR=1.38, 95% CI=1.11-1.71） and Dys （OR=1.75, 95% CI=1.36-2.26）, especially for subjects with H.pylori infection （IM： OR=1.34, 95% CI=1.05-1.71; Dys： OR=1.82, 95% CI=1.37-2.42）. Furthermore, H. pylori infection and PSCA rs2294008 CT/TT genotype were observed to jointly elevate the risk of IM （OR=3.32, 95% CI=2.33-4.71） and Dys （OR=4.58, 95% CI=2.99-7.04）. Conclusion： This study suggested that PSCA rs2294008 might have an impact on the risk of IM or Dys among the high risk population of GC.

PSCA is a critical biomarker for predicting the prognosis of KRAS/TP53 mutant pancreatic cancer patients

Background:Partly due to the limited effect of chemotherapy or other therapeutic strategies,which may be due to the insufficient knowledge of the tumor promotion markers and targets,pancreatic cancer(PC)holds the position of one of the most malignant tumors.This study aims to find a diagnosis/therapeutic molecule that can predict the prognosis of PC with different gene background.Methods:The Cancer Genome Atlas(TCGA)pancreatic duct adenocarcinoma(PAAD)–based single nucleotide polymorphisms and gene expression data were used to find the differentially expressed genes(DEGs)between KRAS/TP53 mutant samples and no gene mutation samples.Gene Set Enrichment Analysis(GSEA)-based Kyoto Encyclopedia of Genes and Genomes(KEGG)analysis and R-based gene oncology(GO)or immune cell invasion assay were used to explore the above DEGs involved pathways.The single-center PC cohort accompanied with next-generation sequence testing was used to verify the TCGA PAAD–based bioinformatic results.Results:First,we found PC patients who harbored KRAS and/or TP53 gene mutation have poor overall survival.Besides,the enrichment analysis showed that mutant KRAS/TP53 was correlated with PC tumor-promotion–related pathways and immune microenvironment.Next,we detected that prostate stem cell antigen(PSCA)was one of the most differential genes in KRAS/TP53 mutant PC tissues.Indeed,the bioinformatic analysis and our clinical data showed that PSCA was a biomarker of poor prognosis in PC.Conclusion:PSCA is a critical biomarker for predicting the prognosis of KRAS/TP53 mutant PC patients.